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I. INTRODUCTION

Biotechnology ventures face much the same business organization issues as
firms in other industries. At the start-up, the founders of the venture must choose
and establish the form (corporation, partnership, etc.) in which to operate the
business. Factors of liability, tax, governance and exit rules influence this choice and
its execution for biotechnology ventures, as these factors do for firms in other fields.
Biotechnology ventures need capital both at their inception and as they grow. This
need for money raises issues of corporate finance and securities law familiar to the
attorney advising businesses in other industries. Biotechnology firms may decide to
reshuffle their capital structure, or to change their form of business organization.
Some owners of the venture might agree to buy out the interests of other owners. A
biotechnology firm might spin-off one line of endeavor into a new firm.
Biotechnology firms might acquire other companies in the field, or be acquired

*
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themselves. Such reorganizations of biotech firms confront issues of corporate, tax,
securities and other laws similar to such transactions involving companies in other
fields.
If all of these issues were no different for the biotechnology venture than for a
generic widget company, we might as well stop this paper now. To make it
worthwhile to focus on the business organization issues facing biotechnology firms,
we must ask what, if anything, is unusual about the biotechnology industry which
might impact the business organization issues faced by firms in the field. A review
of literature concerning the biotechnology industry suggests two significant
differences between business organization issues that biotechnology firms face, and
the business organization issues confronted by companies in other fields.
The first difference is the staggering financial needs of early stage companies
in the biotechnology field. This is not simply a matter of the large dollar amounts
involved with biotechnology research and development-for example, it might
require $350 million to develop, test and obtain approval to market a bioengineered
drug.2 Other industries also have large capital needs. Biotechnology, however,
combines this need for large sums with the possibility of no return on this
investment for years. It can easily take seven or eight years, or longer, to develop a
bioengineered drug, run clinical trials, and obtain the necessary FDA approval to
market the drug. All the while, the company is burning through funds with no
revenues from the project, and no guarantee of anything to show for its effort.3 In
this regard, it is interesting to compare biotechnology firms with companies in
another technology intensive field, the computer industry. A number of observers
have commented on the ability of firms in the computer industry (most recently,
firms involved with the Internet) to make initial public offerings of their stock at
amazing market capitalizations despite the fact that the company has yet to generate
a profit. Nevertheless, these computer companies are actually marketing products
and obtaining revenue, and, when successful, will achieve profitability within a
couple of years. This compares quite favorably with the biotechnology company's
lead time while it patiently waits (and prays) for FDA approval (without which it
may have nothing to sell).
The second difference is the potential for unpredictable and catastrophic liability
from biotechnology development. No sooner will any fan of science fiction 5 hear the
subject of bioengineering crops or drugs, or cloning, than the mind races to the

1.
For an exploration of the issues entailed with forming, financing and reorganizing a business, using an
extended hypothetical problem involving a biotech company, see FRANKLIN A. GEVURTZ, BUSINESS PLANNING (2d
ed. 1995).
2.
E.g., Cynthia Robbins-Roth, Magic Bullets: The Breakthroughs, The Business & The People of
Biotechnology,FORBES, May 31, 1999, at 42.

3.
Id.
4.
E.g., Greg lp & E.S. Browning, Getting Real: What Are Tech Stocks Worth, Now That We Know It Isn't
Infinity?, WALL ST. J., Apr. 17, 2000, at Al.
5.
The author confesses to be one.
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innumerable variations of the "do not fool with mother nature" theme-in other
words, the basic plot in which the scientist, because of hubris, corporate greed, or
desperation at the cut-off of research funds, will rush the genetic alteration
experiment with results ranging from the personal destruction of the scientist, to the
end of civilization as we know it.
Of course, one's first instinct is to dismiss such concerns as the subject for a
symposium on literature, not for a serious piece on the legal problems of
biotechnology. Coincidentally, however, during the preparation of this paper, a
number of articles appeared in the press dealing with the possible impact that
genetically altered corn may have on the monarch butterfly. 6 The corn is known as
Bt corn, and it currently accounts for approximately one quarter of United States'
corn plants. Scientists bioengineered the Bt corn plants to produce a toxin ordinarily
made by a bacteria called Bacillus thuringiensis (hence the label "Bt") which is
found in soil. This toxin is harmless to people and many beneficial insects, such as
honeybees and ladybugs. However, it is poisonous to other insects, including the
corn borer-an insect which causes a billion dollars of damage annually to corn
crops. Hence, the genetically engineered corn produces its own natural pesticide.
Still a potential problem is that the pollen produced by the Bt corn contains the toxin
just like the rest of the plant. As this pollen blows in the wind, it settles on other
plants, including milkweed plants that grow in climates suitable for corn farming.
The monarch butterfly feeds exclusively on milkweeds. This led an entomologist
from Cornell University to see what would happen to monarch caterpillars if they
fed on milkweeds dusted with pollen from Bt corn. The results were not good for
the monarchs.
The purpose of recounting this incident is not to criticize biotechnology or call
for more regulation. In fact, other recent newspaper articles have questioned the
significance of the monarch experiment, since it occurred in a laboratory rather than
in the field.7 What is important for purposes of considering the business organization
issues raised by biotechnology is simply to recognize that the law of unintended
consequences could apply to bioengineered products,8 with the result that a
biotechnology company might one day find itself facing liability for very large
unforeseen damages. 9

6.

All the facts in this discussion are found in Richard A. Lovett, Warning from the Butterflies,

SACRAMENTO BEE, June 20, 1999, at I1.

7.
E.g., Michael Fumento, The World is Still Safe for Butterflies, WALL ST. J., June 25, 1999, at A18.
8.
See Raymond R. Coletta, Biotechnology and the Creation of Ethics,32 MCGEORGE L. REv. 89 (2000)
(discussing unintended consequences of biotechnology).
9.
See Julie A. Davies & Lawrence C. Levine, Biotechnology's Challenge to the Law of Torts, 32
McGEORGE L. REv. 221 (2000). Another example of their potential for unintended consequences occurred while
this paper was in press. It seems that genetically altered corn-approved only for use as animal feed-has found
its way into food products sold for human consumption. E.g., Marc Kaufman, Officials: Biotech Corn Has Spread
in Food Supply, SACRAMENTO BEE, Oct. 19, 2000, at A6.
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As stated in the introduction to this special project, the purpose of these papers
is not to attempt a comprehensive analysis of the issues raised by the development
of the biotechnology industry. Rather, these papers seek to introduce issues and
questions for further exploration. What then are the business organization issues
created by the two differences concerning the biotechnology industry outlined
above? Part I of this paper derives its analysis from the first difference-the
staggering financial needs of the industry. Rather than survey every issue created by
the capital needs of biotechnology development, Part II focuses on one particular
issue: does the choice of business form utilized by those organizing biotechnology
ventures take efficient advantage of tax laws in order to obtain, in effect, a tax
subsidy of these huge expenditures? One reason for this focus is because
biotechnology might provide an interesting comparison case with the
underutilization of tax advantaged forms noted a few years ago in a study of high
technology Silicon Valley start-ups.' °
Part III of this paper focuses on the second difference-the potential for
unpredictable and catastrophic liability. One of the central concerns of corporate or
other business organizations law is the existence of, and exceptions to, limited
liability for the owners of the venture. Part III looks at the challenges posed under
current doctrines concerning limited liability if a biotechnology venture, due to
some unforseen genetic mishap, faces responsibility for damages beyond the
company's ability to pay.
II. FINANCING BIOTECHNOLOGY FIRMS AND THE UTILIZATION
OF TAX ADVANTAGED BusINEss FORMS

A. Tax and Other Aspects of Choice of Business Form
Persons undertaking a business venture, in biotechnology or other fields, can
utilize a number of different forms for conducting the business. Traditionally, these
choices consisted of the sole proprietorship, the partnership, the limited partnership,
and the corporation." Recently, state statutes have created new forms-the limited
liability company' 2 and the limited liability partnership "-as options for conducting

10. See Joseph Bankman, The Structure of Silicon Valley Start-Ups, 41 UCLA L. REV. 1737 (1994)
(referring to biotechnology, electronics, and computing industries centered south of San Francisco and around Route
128 near Boston collectively as "Silicon Valley").
11. GEVURTZ, supra note 1 at 53.
12. See, e.g., Franklin A. Gevurtz, California'sNew Limited Liability Company Act: A Look at the Good,
the Bad and the Ambiguous, 27 PAC. L.J. 261 (1996) (explaining California's statutes creating the limited liability
company).
13. Julia A. Butcher, Note, Business Associationsand Professions;Limited Liability Partnerships-Attorneys
and Accountants, 27 PAc. L.J. 440, 440-47 (1996).
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businesses. 14 In choosing between these forms, there are a number of factors to
consider.
The first factor to consider is the business owners' liability for the debts of the
venture. In the sole proprietorship or partnership, the owners face unlimited personal
liability for all of the business' debts. 5 Given the possibility for unintended
consequences from biotechnology, as discussed in the introduction to this paper,
avoiding, if possible, such unlimited personal liability would be a priority for the
owners of a biotechnology venture. The limited partnership form allows some
owners (the limited partners) to limit their liability for the business' debts, but leaves
other owners (the general partners) with unlimited liability. 16 Corporations, limited
liability companies and limited liability partnerships enable all of the owners to
avoid personal liability for the debts of the firm.17
Management of the business, and the manner of dealing with the departure of
owners, are factors often mentioned in choosing between business forms. 18
Normally, the centralized management structure' 9 and free transferability of
interests 2° in the corporation work very well for a business with numerous owners
(a widely held or publicly held firm). By contrast, the partnership default
approach-with its direct management by all of the owners2 ' and its handling of
owner departure through buy-outs by the other owners rather than transfer to a
stranger 22- is often the preferred choice as far as management and departure rules
for the business with few owners (a closely held or privately held firm). 23 However,
management and departure rules should not substantially impact the choice of
business form for a closely held firm. This is because, under modem corporate

14. Both the limited liability company and limited liability partnership are designed to achieve limited
liability for the owners of the business, but, at the same time, obtain treatment as a partnership under the federal
income tax laws. The difference between the two forms is that a limited liability partnership is a partnership for all
purposes except that, by registering as a limited liability partnership, the partners obtain limited liability (either for
all debts of the firm, or, under some statutes, just for tort claims), whereas a limited liability company is a new type
of entity, the governing rules for which the legislatures took from corporate, limited partnership and partnership
statutes. The primary use of limited liability partnerships has been for professional firms. See, e.g., Walter D.
Schwidetzky, Is It Time to Give the S Corporationa ProperBurial?, 15 VA. TAX REV. 591, 621-24 (1996).
15. E.g., UNIF. PARTNERSHIP ACT § 15, 6A U.L.A. 456 (1914).
16. UNIF. LTD. PARTNERSHIP ACT §§ 303,403(b), 6A U.L.A. 144-45, 177 (1976). One way to avoid having
any individual be personally liable for a limited partnership's debts is to have a corporation act as general partner.
17. FRANKLIN A. GEVURTZ, CORPORATION LAW § 1.1.2a (2000).
18. E.g., Thomas L. Hazen, The Decision to Incorporate, 58 NEB. L. REV. 627 (1979).
19. The owners (the shareholders) elect a small group of individuals (the directors) to be responsible for
governing the business.
20. A shareholder who wants out of the business can sell his or her interest to whomever the shareholder
can find to buy. The buyer picks up all the rights of the seller. The departure does not directly affect the corporation
or the other shareholders.
21. See, e.g., Unif. Partnership Act § 18(e), 6 U.L.A. 526 (1914) (stating that "[aIll partners have equal rights
in the management and conduct of the partnership business").
22. Id. at §§ 27, 31, 38.
23. GEVURTZ, supra note 17, § 1.1.2 (b), (c).
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statutes, it is usually possible for participants to run their corporation, and restrict
transfer of interests in their corporation, like a partnership.24
So far, one might expect most businesses, including most biotechnology
businesses, to operate as a corporation. A corporation can provide limited liability
for the business' owners, as well as management and departure rules which either
are desirable (in the widely held firm) or the owners can contract around (in the
closely held firm). What then accounts for the use, and indeed growth (through the
introduction of the limited liability company and limited liability partnership) of
non-corporate forms? The answer largely lies in the tax laws. The Internal Revenue
Code treats a corporation as a taxpaying entity separate from its shareholders.25 In
contrast, a partnership (or sole proprietorship) is not a taxpaying entity; only the
owner(s) are taxpayers.26 This difference, in turn, often means that large tax savings
hinge upon making the appropriate choice of business form. For example, the tax
code subjects corporate earnings to a double tax; once by the corporation as it makes
money, and again by the shareholders as they receive dividends from the
corporation.27 By comparison, the tax code subjects partnership earnings to a tax
only once; as the partnership makes money, each partner recognizes his or her share
of the firm's earnings as taxable income, but partners generally do not recognize a
distribution of money from the partnership as taxable income.2 8
The difference in the treatment of income, however, is not the most important
tax consideration in deciding the optimum business form for a biotechnology
venture. 29 Rather, as discussed above, the significant fact about biotechnology is the
huge outlays and long lead time required before the business can expect to make
money. Thus, we need to compare how the tax law treats these research and
development outlays when incurred by a corporation and when incurred by a
partnership.
For the corporation, as for any other taxpayer, outlays on biotechnology
research and development generate deductions. 3 ° Being a separate taxpaying entity,
the corporation can subtract these deductions from the corporation's earnings in
computing the company's taxable income. Unfortunately, if the corporation has no
earnings, as is typically the case for a biotechnology start-up, all the company can
do with the net loss resulting from these deductions is wait and hope that in some

24. See, e.g., DEL. CODE ANN. tit. 8, §§ 202, 350,354 (2000). The limited liability company statutes allow
owners flexibility as far as management and departure rules; Gevurtz, supra note 12, at 262-67.
25. See I.R.C. § 11 (2000) (imposing an income tax on corporations).
26. Id. at §§ 701, 702.
27. Id. at § 61(a)(7).
28. Id. at § 731.
29. One caveat about this statement is that the ownership of intellectual property (the biotechnology product)
by a corporation means that a sale of the property and distribution of the proceeds to the shareholders can produce
a significant double tax on the appreciation in value (from nil to potentially billions of dollars) which has occurred
to the property by virtue of its creation. Ownership of the intellectual property by a non-corporate entity avoids this
double tax.
30. See, e.g., I.R.C. §§ 162(a), 174.
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future year it will generate earnings against which the company can subtract the
carried over Ioss. 3 1 Yet, there is a very good chance with biotechnology that the
product will never pan out and there never will be earnings against which to offset
the carried over losses. In this event, the potential for tax savings will be gone. Even
if things eventually do work out, the long lead time in biotechnology development
renders the carried over losses less valuable than if used immediately (because of the
time value of money). Moreover, the inevitable need for biotechnology ventures to
seek additional financing can limit the use of the carried over losses by virtue of
Section 382 of the Internal Revenue Code.32
By contrast, since the partnership (or proprietorship) is not a separate taxpaying
entity, any deductions generated by the business flow through to the owner(s). As
a result, the partner (or proprietor) might be able to subtract deductions generated
by biotechnology research and development from income the partner made in other
activities when computing the partner's net taxable income for the year. In other
words, the partner can use the deductions to shelter other income from taxation.
Congress has added a number of provisions to the Internal Revenue Code to limit
such tax sheltering. Most significantly, Section 469 curbs a taxpayer's use of losses
33
from so-called passive activities to offset income from non-passive activities.
Section 469, however, does not remove all utility from flowing losses through to a
business' owners. For example, Section 469 does not limit the use of losses by
widely held corporations.34 For reasons we shall discuss later, this exception for
widely held corporations is potentially of great significance to biotechnology.
At this point, there appears to be a trade-off between the form of business most
desired to limit liability for the venture's owners (the corporation), and the form of
business with the most desirable tax treatment (the partnership or sole
proprietorship). The limited liability partnership, limited liability company and
limited partnership, however, allow owners to obtain limited liability and also
partnership-style tax treatment.35 It is also possible to operate a business through a
corporation and yet obtain tax treatment largely similar to the treatment of
partnerships.36 Corporations which elect this partnership style taxation are known
as "S corporations." Finally, we should note that these tax considerations cease to
have relevance to a business once it is publicly held. This is because the tax code
treats publicly traded partnerships the same as corporations.37 Accordingly, the
31. Id. at § 172.
32. Id. at § 382. This provision is designed to prevent the trafficking in loss carry-overs. In the event of a
fifty percent or greater change in the ownership of a corporation, the Section imposes a rather complex limit on how
much of any net operating loss carry-overs the corporation thereafter can use.
33. id. at § 469.
34. Id. at § 469(a) (2000). Widely held corporations might incur deductible losses not only in their own
internal activities, but also in the role of partner in a partnership.
35. See Treas. Reg. § 301.7701-3 (2000) (allowing non-corporate entities to elect taxation as a corporation
or as a partnership).
36. I.R.C. §§ 1361-1379 (1988 & Supp. 2000).
37. Id. § 7704.
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publicly held business may as well operate as a corporation, with the management
and transfer rules best adapted for publicly traded firms.
B. The Experience With High Technology Start-Ups Generally
The discussion above suggests we should expect to find that publicly held firms
operate as corporations, but we should expect to find that start-up ventures in high
technology fields operate in non-corporate forms. After all, ventures normally do not
start life as publicly held and, therefore, precluded from partnership-style tax.
treatment. Moreover, the high technology start-up normally expects to incur tax
deductible losses for at least a few years. A study in the early 1990s of Silicon
Valley start-ups by Professor Joseph Bankman found, however, that reality did not
correspond with this expectation.3 8 Rather, Silicon Valley start-ups overwhelmingly
were corporations (which evidently did not elect Subchapter S treatment). The result
was the loss of millions of dollars of tax savings.
Professor Bankman conducted interviews with participants in Silicon Valley
companies to inquire why they utilized the corporate form rather than a more tax
advantaged organization. The answers to his inquires provided a number of
rationalizations:
(1) Saving transaction costs which a non-corporate start-up would incur to
incorporate later when the firm decided to make an initial public
offering (albeit, the cost of reorganizing a non-corporate business into
a corporation in order to go public was often far less than the tax
39
savings forfeited by not having started life in the non-corporate form);
(2) The desire to use stock options to compensate employees in Silicon
Valley companies (albeit, non-corporate businesses could create
similar, although less familiar and therefore less readily accepted,
ownership options); 4°
(3) The fact that investors in Silicon Valley start-ups often are tax exempt
institutions (such as universities) who could not use tax deductible
losses to offset other taxable income (albeit, this raises the "chicken and
egg" question as to whether Silicon Valley start-ups ignore tax savings
because their investors are often tax exempt institutions, or whether tax
exempt institutions are often the persons investing in Silicon Valley
start-ups because Silicon Valley start-ups ignore tax savings); 41 and

38.
39.
40.
41.

See Bankman, supra note 10, at 1747-66.
Id. at 1749-51.
Id. at 1750-53.
Id. at 1753-64.
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(4) the mentality of the owners of Silicon Valley businesses to so focus on
the big payout from success to the extent that they feel they can ignore
concerns about tax savings.42
C. Should We Expect Biotechnology to be Different?
Professor Bankman defined his sample of high technology firms
geographically-high technology firms operating in the area south of San Francisco
and along Route 128 near Boston. This lumped together biotechnology, computer
and electronics firms. It is interesting to ask whether a study which focuses only on
biotechnology firms, without regard to geography (except that the firms be
organized in the United States 43), would obtain the same result."
There is no a priori reason to assume that the overall biotechnology industry
would display the same attitude toward tax savings as found among Silicon Valley
start-ups consisting presumably for the most part of computer and electronics firms.
The disregard of tax savings documented in Professor Bankman's study is not
characteristic of businesses in general. Many industries, notoriously including real
estate, have been highly sensitive to tax advantages. Indeed, the rapid-fire spread of
legislation establishing the limited liability company is testimony to the interest in
the business world in obtaining partnership tax treatment.
The primary reason to expect that principals organizing biotechnology ventures
might be sensitive to tax advantages lies in the staggering capital needs of the
industry. It is one thing for the principals in an Internet company like Yahoo, Inc.,
which went public nine months after its founding, to figure that obtaining flowthrough tax treatment of less than one million dollars worth of operating losses45 was
not worth worrying about. It is quite a different matter to be so cavalier about tax
write-offs of $350 million invested to develop a bioengineered drug, when it could
be eight years before there will be a marketable product, and often there is a good
chance there will be no a marketable product at all.
Offsetting this economic factor, we must ask to what extent the various
rationalizations reported by Professor Bankman for Silicon Valley firms to ignore
the tax advantages of non-corporate forms apply with equal force to biotechnology
businesses. The economic realities of the biotechnology industry just discussed, as
compared with the computer industry, would seem to make it much more difficult
for the principals in biotechnology firms to so focus on the venture's inevitable
success that they feel justified in ignoring the more immediate utility of tax savings.

42. Id. at 1764-66.
43. Firms organized outside of the United States may have somewhat different choices of business forms
available to them, and somewhat different tax incentives.
44. It is also interesting to ask if the result for high technology firms will have changed in the last five years,
given the growing availability of new non-corporate business forms (like the limited liability company).
45. GEVURTZ, supra note 1, at 80 (Supp. 1998).
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By contrast, at the time of Professor Bankman's study, the view that high
technology firms should start life as a corporation because the business soon will go
public, might have had as much basis for the biotechnology industry as it did for the
computer industry. Biotechnology stocks in the 1990s, however, for the most part
seem to have not faired as well as computer industry stocks. As a result, the stock
market has become much less inviting for initial public offerings by biotechnology
companies. 46 Hence, one might expect more recently formed biotechnology start-ups
to give less thought to choosing a form of business organization based upon the
expectation of an initial public offering in the near future.
It is unknown if there is much difference between biotechnology and other high
technology start-ups in the desire to use stock options to compensate employees, and
whether employees in biotechnology companies would be as suspicious as
employees in other high technology start-ups of an offer of ownership options in a
non-corporate business.
The nature of the investors in biotechnology cuts both ways when it comes to
interest in flow-through treatment of business losses. The presence of tax exempt
investors (who would not be interested in flow-through tax losses) may well be a
more inevitable phenomenon for biotechnology than for the computer industry.
After all, initial funding of drug research often comes from the National Institute of
Health. Moreover, much biotechnical research takes place at universities.47 This can
lead universities not only to license the right to use results of the universities'
research to biotechnology firms in exchange for cash royalties, but also to seek
equity positions in the biotechnology firms.48 On the other hand, established
pharmaceutical firms have provided an increasingly important source of financing
for early stage biotechnology companies. 49 As mentioned earlier, the limitations
imposed by the tax code on the ability to offset losses from passive activities against
other income made by a taxpayer do not apply to public corporations, such as these
established pharmaceutical firms. Hence, these established pharmaceutical
companies provide the perfect investors to take advantage of the tax write-offs
entailed in biotechnology development.

46. See, e.g., Larry Fisher, Money Walks: VCs Are Bailing on Biotech, FORBES, May 31, 1999, at 77. The
market for biotech stocks staged a dramatic upturn while this article was in press; Suzanne McGee & Robert
McGough, Signs of Life: Tick, Tick, Tick: How Once-Sluggish Biotech Finally Went Boom!, WALL ST. J., Mar. 17,
2000, at Al. Still, it is impossible to predict (or else I could become rich) whether biotech stocks will tank again.
47. Dan L. Burk, Introduction:A Biotechnology Primer,55 U. PITr. L. REV. 611, 629 (1994).
48.

See, e.g., Gregory B. Abbott, Pharmaceuticaland Biotech Licensing and Joint Ventures, 514 PLI/Pat

37, 47-48 (1998).
49. Id. at 48-52. Since 1990, established pharmaceutical companies have made over two billion dollars worth
of minority position equity purchases in biotechnology companies. Established pharmaceutical companies have
provided additional financing to biotechnology companies through loans repayable in cash or in stock or by reduced
royalties under a licensing agreement, and through licensing agreements covering the product under development,
which call for development-phase payments by the pharmaceutical company. Id.
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D. Survey Results
In order to investigate the choice of business form made by biotechnology
companies, my research assistant undertook surveys. First she conducted an Internet
search for a web site which contained a list of biotechnology companies. The site
she located is "www.biospace.com." From information supplied at this site, or by
contacting the company directly, she was able to determine the form of business for
130 biotechnology companies listed at the site. Since, for reasons discussed above,
publicly held firms are usually corporations, I asked her to identify, if possible,
which firms in her sample were public and which firms were private. In addition,
since limited liability companies only recently have become a realistic option for
businesses, I asked her to establish, if possible, what year the biotechnology
companies were formed.
The results of this survey are attached to this paper as Appendix A. Of the 130
companies at this site, seventy-three are public corporations, fifteen of the remainder
are subsidiaries of other corporations, 0 thirty-six are privately held corporations,
four are limited liability companies, and two are sole proprietorships. In other
words, only six out of forty-two non-public and non-subsidiary biotechnology firms
chose a form of business which would optimize the tax utility of biotechnology
research expenditures. As expected, the use of limited liability companies is a recent
phenomenon: one of the four biotechnology limited liability companies in the
sample was formed in 1993, one in 1996, and two in 1997. Yet, even in 1997, the
sample included the formation of eight privately held biotechnology corporations,
as compared with only two limited liability companies.
In addition to the web site survey, my research assistant used information
published by the Sacramento Business Journal to investigate the choice of business
entity made by Sacramento area biotechnology firms. The results also are attached
to this paper as Appendix B. Overall, the results are consistent with the web site
survey. Of the eleven Sacramento area biotechnology firms which are neither
publicly held nor a subsidiary of another company, eight are organized as privately
held corporations, one is a sole proprietorship, and two are limited liability
companies. 1 Interestingly, however, the only Sacramento area biotechnology firm
formed since 1996 is a limited liability company.52 This timing is potentially
significant because California's limited liability company statute took effect in
1995." 3 The sample is far too small, however, to show that even in the Sacramento

50. If these subsidiaries are at least eighty percent owned by their parent corporations, the parent
corporations can gain the advantage of offsetting the subsidiaries' biotechnology development expenses against the
parents' other income by filing consolidated tax returns. I.R.C. §§ 1501-1504 (1998 & Supp. 2000); Treas. Reg.
§ 1.1502-21T (as amended in 1998).
51. See Table 2 infra (summarizing 1998 and 1999 SACRAMENTO BUSINESS JOURNAL articles).
52. Id.
53. See Butcher, supra note 13, at 440-47.
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area, privately held biotechnology firms will shift to make greater use of tax
advantaged forms.
E. Caveats and Suggestionsfor FurtherInvestigation
The results of these surveys suggest that biotechnology companies generally
have made little use of tax favored business forms-albeit this may have recently
begun to change in Sacramento. The goal of this study, however, was simply to gain
a preliminary understanding of the data, rather than to undertake any sort of
statistically rigorous investigation. Hence, the sample was selected based upon
convenience of data collection, rather than working through a comprehensive list of
all biotechnology companies. Such a comprehensive list would include
approximately 1200 biotechnology companies, of which three-quarters are privately
held.54 Still, there is no reason to believe that the samples were unrepresentative with
respect to selection of business form.
In addition, it is possible that owners of privately held biotechnology
corporations have found a way to deduct development expenses against their other
income despite the use of the corporate form. Perhaps some of these private
biotechnology corporations have elected taxation under Subchapter S. This seems
unlikely, however, because of the one class of stock requirement for electing
taxation as an S corporation. 55 The one class of stock requirement precludes the
corporation from issuing the preferred stock which venture capital firms and similar
investors desire. Alternately, perhaps established pharmaceutical corporations who
provide funds to early stage biotechnology companies are obtaining the advantage
of tax write-offs through licensing deals. Specifically, licensing agreements between
established pharmaceutical companies and early stage biotechnology companies
usually provide for some payments by the pharmaceutical companies to the
biotechnology companies while the product to be licensed to the pharmaceutical
company is still under development.56 Perhaps the pharmaceutical companies are
writing off these development-phase payments as ordinary business expenses. While
such payments constitute income to the biotechnology company, the development
expense deductions "wash out" this income. The end result would be a self-help
partnership-style tax treatment despite use of the corporate form. On the other hand,
use of this technique by pharmaceutical companies to claim tax deductions (if, in
fact, this is what the companies are doing) might be subject to challenge by the
Internal Revenue Service. The problem is that such development-phase payments
might constitute non-deductible capital expenditures made to acquire the value
entailed in the later license rights, rather than an immediately deductible ordinary

54.
55.
56.

Abbott, supra note 48, at 46.
I.R.C. § 1361(b)(1)(D) (2000).
Abbott, supra note 48, at 57-58.
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and necessary business expense. The topic of when a taxpayer must capitalize,
rather than deduct immediately, payments made to achieve long term benefit has
become even murkier as a result of the U.S. Supreme Court's decision in
INDOPCO,Inc. v. Commissioner,5 8 and is well beyond the scope of this paper. At
any event, further investigation of this area would call for contacting privately held
biotechnology corporations to determine whether they are managing in some manner
to pass loss deductions through to their owners or suppliers of capital despite the
choice to operate in the corporate form.
III. LIMITED LIABILITY FOR OWNERS OF BIOTECHNOLOGY VENTURES

A. Piercing the Corporate Veil
As discussed in Part II of this paper, the desire of participants in a business to
avoid personal liability for the venture's debts is one, if not the primary, factor in
choosing to conduct business through a corporation.5 9 Nevertheless, when a
corporation is unable to pay its debts, creditors of the corporation often sue one or
more of the shareholders, and urge the court to disregard the normal rule that
shareholders are not personally liable for the corporation's debts. 6° The popular
name for imposing such personal liability upon the shareholders is "piercing the
corporate veil., 61 Accordingly, if a biotechnology calamity produces damages
beyond the company's ability to pay, we should expect to see creditors sue some or
all of the owners of the biotechnology company in an action urging the court to
pierce the corporate veil and impose personal liability upon the owners.
In piercing the corporate veil cases, courts almost invariably begin at the same
point of departure: piercing is an equitable remedy the court can impose in order to
avoid injustice.62 Unfortunately, once courts go beyond this broad generality,
piercing the corporate veil doctrine turns into something of a muddle.63 The primary
factors recited by courts and writers suggesting that the owners should not be
shielded from liability include: (1) the defendant shareholder's control over the

57. Because the pre-development payments are to acquire license rights, presumably the pharmaceutical
company could not use Section 174 of the Internal Revenue Code to avoid capitalization treatment-even though
the money ultimately funds research and development.
58. 503 U.S. 79 (1992).
59. Participants can also limit liability by conducting business through another entity, such as a limited
liability company.
60. In fact, such claims make up the single most litigated area in corporate law. Robert B. Thompson,
Piercingthe Corporate Veil: An Empirical Study, 76 CORNELL L. REv. 1036, 1036 (1991).
61. Although we cannot speak literally of piercing the "corporate" veil when dealing with a limited liability
company, the same general doctrine presumably applies in the limited liability company context. E.g., Ditty v.
CheckRite, Ltd., 973 F. Supp. 1320 (D. Utah 1997); CAL. CORP. CODE § 17101(b) (West Supp. 2000).
62. See, e.g., DeWitt Truck Brokers v. W. Ray Flemming Fruit Co., 540 F2d 681, 683 (4th Cir. 1976).
63. For a comprehensive exploration of this area, see Franklin A. Gevurtz, PiercingPiercing:An Attempt
to Lift the Veil of Confusion Surrounding the Doctrineof Piercing the Corporate Veil, 76 OR. L. REv. 853 (1997).
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corporation; 64 (2) failure to observe corporate formalities; 65 (3) fraud or other
wrongful conduct by the defendant shareholder in dealing with the plaintiff
assets
creditor; 66 (4) siphoning, commingling or other misuse of the corporation's
68
67
by the defendant shareholder; and (5) inadequate capitalization.
In the context of a biotechnology mishap, the corporation would most likely
face tort, rather than contract, liability. Put differently, courts would probably be
dealing with the claims of persons who had not voluntarily extended credit to the
corporation. The traditional wisdom has been that courts are more likely to pierce
the corporate veil in favor of such involuntary or tort claimants (as opposed to
voluntary or contract creditors).69 In fact, however, an empirical study of piercing
decisions in the Westlaw database found that courts actually pierced in a higher
percentage of contracts as opposed to torts cases 7 -albeit, this simply might
represent the fact that perhaps the most common ground for piercing (fraudulently
inducing extensions of credit to the corporation) can be relevant to the claims of
contract creditors, but is irrelevant to the claims of tort victims.7
When confronting a piercing claim arising out of a biotechnology calamity, the
most salient ground for piercing probably would be inadequate capitalization. Court
opinions differ on the degree to which inadequate capitalization constitutes grounds
for piercing the corporate veil.72 Most courts avoid the issue by stating that
inadequate capitalization is a factor to consider, without specifying the impact of
this factor.73 At any event, the real challenge if a biotechnology mishap produces
cataclysmic damages will be to figure out what constitutes inadequate capitalization.
The biotechnology company might have considerable capital in the sense of dollars
paid as equity investment in the companies-after all, biotechnology development
demands large amounts of capital-but the damages from a truly cataclysmic
biotechnology disaster could dwarf this equity investment. From a policy standpoint,
the purpose of piercing the corporate veil in favor of tort victims based upon
inadequate capitalization is to force those in charge of corporations to internalize the
costs of accidents into the costs of goods or services.7 4 Such internalization takes
place through paying insurance premiums. Hence, the criterion for adequate

64. Thompson, supra note 60, at 1063 (defendant's control over the corporation mentioned as a factor for
piercing in 551 of the approximately 1600 piercing decisions surveyed in this study).
65. E.g., Sea-Land Services, Inc. v. Pepper Source, 941 F.2d 519 (7th Cir. 1991). But see Gevurtz, supra
note 63, at 866-70.
66. E.g., DeWitt Truck Brokers, 540 F.2d 681.
67. E.g., Sea-Land Services, 941 F.2d 519.
68. E.g., Minton v. Cavaney, 364 P.2d 473 (Cal. 1961).
69. E.g., Frank H. Easterbrook & Daniel R. Fischel, Limited Liability and the Corporation, 52 U. CHI. L.
REv. 89, 112 (1985).
70. Thompson, supra note 60, at 1058.
71. Gevurtz, supra note 63, at 859.
72. Compare Minton, 364 P.2d 473, with Walkovszky, 223 N.E.2d 6.
73. E.g., DeWitt Truck Brokers, 540 F.2d at 685-87.
74. Gevurtz, supra note 63, at 887.
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capitalization in the tort claim context should be whether the corporation had
adequate insurance for foreseeable risks of its business.75 Unfortunately,
biotechnology presents challenges which differ in substantial degree from those in
other industries. It is one thing to measure the foreseeable risks of a taxicab business
to decide whether $10,000 of liability insurance constitutes adequate capitalization.76
It is quite a different matter to determine what level of insurance is adequate to deal
with the possibility that, like the Bt corn, some biotechnology product or experiment
falls victim to the law of unintended consequences.
Now let us shift our discussion from the nature of the probable plaintiffs and
their likely theory for piercing, to who will be the likely defendants when a piercing
claim arises out of a biotechnology mishap. One probable defendant would be the
biotechnology company's parent corporation. The web site survey reported in Part
II, supra, illustrated that a fair number of biotechnology firms are subsidiaries of
other corporations. These parent companies are typically the sort of major
corporations whose deep pockets make a piercing claim attractive. While there is
some authority arguing that courts should be more willing to pierce against a parent
corporation than against an individual who is a controlling shareholder,7 7 neither
judicial doctrine7 8 nor the statistical results of piercing decisions 79 reflect such a
view. At any event, a piercing claim against a parent corporation in the event of a
biotechnology calamity will force courts to confront the same sort of issues which
have already arisen in situations in which a subsidiary's actions have produced mass
tort claims (such as with asbestos, silicon breast implants, and similar cases).80 For
example, courts must decide to what extent a parent's control over the subsidiary
should become grounds to pierce. In fact, in some previous mass tort cases, the
parent's control over the very technology which led to the mass tort has been so
extensive that courts have been able to hold the parent liable for the negligence of
the parent corporation's own personnel, and thereby probably avoid the whole issue
of whether to pierce the subsidiary.8 ' If, however, the parent merely exercises
general control over the business of the biotechnology subsidiary, and is not itself
a party to creating the mishap, their general control probably is a necessary, but not
a sufficient, ground for piercing.82 In addition to the impact of control, a calamity
involving a biotechnology subsidiary might force a court to confront the policy issue

75. See, e.g., Radaszewski v. Telecom Corp., 981 F.2d 305, 308-09 (8th Cir. 1992).
76. See Walkovszky, 223 N.E.2d at 7.
77. Easterbrook & Fischel, supra note 69, at 110-11.
78. In fact, courts tend to cite and apply piercing precedent without regard for whether the shareholders
involved were individuals or parent corporations. Gevurtz, supra note 63, at 896-97.
79. Thompson, supra note 60, at 1056 (finding that courts pierced in a slightly higher percentage of cases
when the shareholder defendant was an individual, as opposed to a parent corporation).
80. See, e.g., In re Silicone Gel Breast Implants Prod. Liab. Lithog., 887 F. Supp. 1447, 1452-53 (N.D. Ala.
1995).
81. Id. at 1453-54.
82. Gevurtz, supra note 63, at 862-66.
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of whether large companies should be able to place more hazardous ventures in
separate corporations in order to insulate the wider enterprise from liability.
One interesting prospect with biotechnology, which might distinguish it from
other mass tort situations in recent years, is that the mishap might occur in the early
stage of product development.83 In this event, the biotechnology corporation might
84
be a fairly new company which is neither a subsidiary nor a publicly traded firm.
In such a scenario, the targets of a piercing suit could include venture capital firms,
universities, or the like, who were investors in the biotechnology company-since
the individuals actively running the company might possess insufficient wealth,
outside of their interest in the company, to make a piercing suit against such
individuals worthwhile. Courts generally will not pierce against passive shareholders
in a failed corporate debtor.8 5 Venture capital firms, however, often insist on taking
a fairly active role in their portfolio companies.86 Whether the sort of guidance
which a venture capital firm supplies would be sufficient to justify holding the
venture capital firm liable in a piercing case-assuming there is grounds for
piercing, such as inadequate capitalization-is an interesting question upon which
there is little, if any, authority.87
B. Licensing and CooperativeActivities
As mentioned in Part II supra, licensing agreements and other cooperative
arrangements between developmental stage biotechnology development companies
and established pharmaceutical firms have become an important source of financing
in the biotechnology industry. If a pharmaceutical company, pursuant to its license
rights, sells a biotechnology product that turns out to be dangerous, then the
pharmaceutical company can face direct liability for its own possible tort. Suppose,
however, the research activities of a development stage biotechnology company
create a biotechnology. calamity prior to the full development of a biotechnology
product that is subject to a licensing agreement. In this event, is there any theory
under which the pharmaceutical company licensee could end up liable?
One theory is that the biotechnology company and the pharmaceutical company
are not simply licensor and licensee, but are partners in a partnership. As a partner,
the pharmaceutical company would face unlimited personal liability for any debts

83. In other words, a situation in which the mishap involves the escape of a genetically altered product,
rather than the sale of the product to consumers who are then injured.
84. Courts have never pierced against the shareholders of a publicly held firm. Thompson, supra note 60,
at 1047.
85. Id. at 1056.
86.

E.g., GEVURTZ, supra note 1, at 582.

87. In a noted opinion, the California Supreme Court held that an individual who had an active, but by no
means dominant, role in a corporation-the individual being an attorney who did the legal work to form the
company and acted as one of the company's directors-could be liable when the court pierced the corporation on
the ground of inadequate capitalization. Minton v. Cavaney, 364 P.2d 473, 474-76 (Cal. 1961).
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of the partnership, including liabilities resulting from torts committed by the
biotechnology company in the course of the partnership's development of the
biotechnology product.8" In order for the pharmaceutical company and the
biotechnology company to be partners, the two companies must be carrying on, as
co-owners, a business for profit.8 9 It is often not easy to tell when two or more
persons are acting as co-owners of a business for profit, as opposed to being simply
lender and borrower,9° employer and employee, 91 or, in this situation, licensor and
licensee. The two primary indicators of co-ownership are a sharing of profits and a
sharing of control. 92
Under the Uniform Partnership Act, receiving a share of the profits of a business
is prima facie evidence that the recipient is a partner. 93 Biotechnology license
agreements generally call for royalty payments based upon a percentage of net
sales.94 The agreement often limits the number of items that may be subtracted from
gross revenues in computing net sales in order to prevent net sales from equaling net
profits, thereby triggering prima facie partner status. 95 Still, the sharing of the
income stream from the biotechnology product inherent in the license-royalty
arrangement is hardly inconsistent with the possibility that the two firms really are
partners.
Control also depends upon the license agreement. Many such agreements
establish management committees, composed of representatives of the
pharmaceutical company and representatives of the biotechnology company, "to
96
review project progress, establish timelines and responsibilities and set budgets.
There may also be a separate research committee, composed of scientists from both
97
firms, to conduct scientific reviews of the project and engage in planning. This
collaborative management of a research project seems to go beyond the consultation
98
and veto rights which court opinions have held not to create partner status.

88. E.g., UNIF. PARTNERSHIP ACT §§ 13, 15, 6 U.L.A. 444, 456 (1914).
89. Id. at § 6(l).
90. See, e.g., Martin v. Payton, 158 N.E. 77 (N.Y. 1927).
91. See, e.g., Vohland v. Sweet, 433 N.E.2d 860 (Ind. Ct. App. 1982).
92. See, e.g., Martin, 158 N.E. at 220-23.
93. UNIF. PARTNERSHIPACT § 7(4),6 U.L.A. 280 -281 (1914). This provision excludes from the prima facia
evidence characterization receipt of a share of the profits under a variety of circumstances, including rent to a
landlord, but does not expressly exclude receipt of a share of profits as royalties from such characterization.
94. Abbott, supra note 48, at 58.
95. Id.
96. Id. at 52-53.
97. Id.at 53.
98. See, e.g., Martin, 158 N.E. at 79-80. This discussion suggests that the current structure ofbiotechnology
licensing agreements might achieve the worst of both worlds. For reasons discussed in Part 1[of this paper, these
agreements might not allow the pharmaceutical company to take an immediate tax deduction for development-phase
payments made to the biotechnology company, as the pharmaceutical company could have if it formed a partnership
for tax purposes with the biotechnology company. At the same time, state courts might treat the license arrangement
as a partnership for purposes of imposing liability upon the pharmaceutical company. A better structure might be
to form a research limited liability company between the biotechnology company and the pharmaceutical company.
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C. Business Acquisitions and Dispositions
Liability issues under business organizations law also can arise if a catastrophic
mishap occurs following a variety of reorganization transactions, including mergers
or other acquisitions of biotechnology companies, dissolutions of biotechnology
companies, and spin-offs of biotechnology companies. The underlying concern in
all of these transactions comes from the prospect that a biotechnology company has
planted the seeds (pun not intended) for a biotechnology mishap prior to the
transaction, which then produces a calamity after the transaction. One possible
scenario is common to defective product cases. 99 A biotechnology product already
sold by the biotechnology firm might cause harm after an acquisition, dissolution
or spin-off involving the firm. An alternate scenario might involve a development
stage mishap, which only becomes known and produces harm after the acquisition,
dissolution or spin-off. This is a parallel to, and indeed, in some cases might come
within, the situations in which purchasers of businesses or property face liability
under federal environmental statutes as a result of the earlier owner's disposal of
hazardous waste.' m
In a merger involving a biotechnology company, the surviving firm will pick up
all of the liabilities of the biotechnology corporation-including liabilities for any
pre-merger biotechnology mishaps which later come home to roost-by operation
of law. 1° ' If, on the other hand, the parties to the acquisition of a biotechnology
company structure the transaction as a sale of assets by the biotechnology company
to the other firm, then, under traditional corporate law, the purchasing company will
not become liable for the biotechnology company's debts unless the purchasing
company agrees to assume the debts. 102 An exception to this avoidance of liability
exists if the court treats the purchase as a "de facto merger." Whether a court will
treat an asset purchase as a de facto merger can depend upon whether the purchasing
company picks up the selling firm's organization, management and personnel
(which makes the transaction look more like a merger), how long and how actively
the selling company continues to exist after the sale (the longer and more actively
the selling company continues after the sale, the less the transaction looks like a
merger), and, most critically, whether the sale is for cash or for stock in the
purchasing corporation (cash consideration rules out defacto merger

99. See, e.g., Ramirez v. Amsted Indus, Inc., 431 A.2d 811 (N.J. 1981).
100. See, e.g., New York v. Shore Realty Corp., 759 F.2d 1032 (2d Cir. 1985) (purchaser of contaminated
property held liable under the Comprehensive Environmental Response, Compensation, and Liability Act
(CERCLA), 42 U.S.C. §§ 9601-9675 (1982)).
101. E.g., DEL. CODE ANN. tit. 8, § 259(a) (1991).
102. E.g., McKee v. Harris-Seybold Co., 264 A.2d 98 (N.J. Super. Ct. Law Div. 1970), aft'd, 288 A.2d 585
(N.J. Super. Ct. App. Div. 1972). An acquisition structured as the purchase of stock in the biotechnology company
by the acquiring firm creates a parent subsidiary situation. Hence, liability for the acquiring firm in a stock
acquisition depends upon whether a court will pierce the corporate veil.
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characterization). 103 Some courts, however, have gone beyond this narrow exception
and have held that a corporation which acquires and continues a product line will
be liable when a product of that line turns out to be defective, even though the
defective product was sold before the defendant corporation purchased and took
over the product line. 1°4
Dissolution of a biotechnology company raises similar concerns about liability
based upon events prior to the dissolution which lead to unexpected damages after
dissolution. With a dissolution, however, the concern is not liability of the acquiring
company, but rather the liability of the shareholders of the dissolved firm. Normally,
upon dissolution, the corporation must pay off its creditors before distributing
whatever assets are left to its shareholders.1 05 Failure to do so can lead to liability for
the recipient shareholders under both common law and statutory theories. 10 6 The
problem, however, is that it is difficult for the corporation to pay a claim which is
unknown to the company before the distribution of assets. State corporation statutes
often contain provisions allowing corporations to cut off claims after a certain length
of time if the corporation gives notice of its dissolution. 17 On the other hand, if a
biotechnology company's management were aware of the mishap and then decided
to dissolve the company and distribute its assets with the plan of avoiding payment
of claims, there could be liability.'0 8
In a spin-off, the stock of a new corporation is distributed to the shareholders
of an existing corporation out of whose assets the new corporation was formed. The
end result is to create two independent corporations. This is the opposite of a merger
or acquisition. Spin-offs create the issue of whether a corporation can avoid liability
for a biotechnology calamity by spinning off a biotechnology company, when the
roots of the mishap may have existed before the spin-off, but the damage only
occurred after. Resolving this issue could confront the court with the difficult task
of deciding when the claim accrued-before the spin-off (in which case, the
preexisting corporation cannot escape responsibility for its own tort by forcing the
plaintiffs to sue the new corporation'°9), or after the spin-off (in which case, liability
would appear to fall only on the spun off company).
IV. CONCLUSION
The brave new world of biotechnology confronts a host of legal issues,
including issues concerning business organization. This paper has introduced two
of the business organization issues: (1) whether biotechnology firms are choosing

103.
104.
105.
106.
107.
108.
109.

E.g., Shannon v. Samuel Langston Co., 379 F. Supp. 797, 801 (W.D. Mich. 1974).
E.g., Ray v. Alad Corp., 560 P.2d 3 (1977).
E.g., DEL. CODE ANN. tit. 8 § 281(a) (1990).
Id. § 282.
Id. §§ 280, 282(b).
See, e.g., Pacific Scene, Inc. v. Penasquitos, Inc., 758 P.2d 1182 (Cal. 1988).
See, e.g., Darcy v. Brooklyn & N.Y. Ferry Co., 127 A.D. 167 (N.Y. App. Div. 1908).
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their form of business to make efficient use of tax laws in financing biotechnology
development, and (2) whether the parties involved in biotechnology will be able to
avoid personal liability if the law of unintended consequences results in a
biotechnology product wiping out more than perhaps some monarch butterflies.
These are subjects worthy of further exploration.
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APPENDIX
TABLE 1: www.biospace.com
Year
Incorporated
or Founded

Public
Corporation

Pre-1980

Private
Corporation

Sole
Proprietorship

LLC

1

1980
1981

1

1

Subsidiary

TOTAL

6

7

1

1

1

3

1982

0

1983

0

1984

1

1

1985

2
0

1986

1

1

1987

0

1988

0

1989

1

1

2

1990

3

1

4

1991

8

1

9

1992

6

3

1993

5

3

1994

6

4

1995

8

3

1996

22

8

1997

8

8

1998

3

1

1999

1

1

TOTAL

73

36

1
1

10
9
10

1

12

1

2

33

2

1

19

1

5
2

1

4

15

129

257
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SUMMARY OF TABLE 1: Statistics Obtained from www.biospace.com on June 7, 1999
Public Corporations

73

56.2%

Private Corporations

36

27%

Subsidiaries

15

11.5%

LLC

4

3.1%

Sole Proprietorships

2

(for one the date the

1.5%

company began was
unavailable and was not
included in Table 1)

Partnerships

0

0%

TOTAL BIOTECH COMPANIES

130

100%
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TABLE 2:
Year
Established
in.
Sacramento
Area

Sacramento Business Journal-Top 25 List of Biotech Companies 1999'0
Public
Corporation

Pre-1980

Private
Corporation

Sole
Proprietorship

2

1980
1981

LLC

Subsidiary

TOTAL

2

4

1
1

1

1

2

1982

0

1983

0

1984

0

1985

1

1986

1

1
1

2

1987

0

1988

0

1989

1

1990

1
0

1991

1

1992
1993

1

2

1

1

1

1

1994

0

1995

1

1

1996

0

1997

0

1998
TOTAL

1
1

8

1

2

1
5

17

110. Top 25 List of Biotech Companies, SACRAMENTO Bus. J., Apr. 9, 1999, at 133; Top 25 List of Biotech
Companies, SACRAMENTO Bus. J., Apr. 3, 1998, at 51.
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SUMMARY OF TABLE 2: Statistics Obtained from Sacramento Business Journal-Top 25

List of Biotech Companies
Public Corporations

1

5.9%

Private Corporations

8

47%

Subsidiaries

5

29.4%

LLC

2

11.8%

Sole Proprietorships

1

5.9%

Partnerships

0

0%

TOTAL BIOTECH COMPANIES

17

100%

